SUMMARY We studied 16 patients with severe mitral regurgitation to determine the acute effects of hydralazine on cardiac performance at rest and during exercise and to assess the long-term clinical response to therapy. At rest, optimal-dose hydralazine (range 50-225 mg) reduced systemic vascular resistance from 1385 ± 88 to 964 ± 76 dyn-sec-cm-5 (mean ± SEM) (p < 0.001). As a result, pulmonary artery wedge pressure decreased from 18 ± 2 to 15 ± 2 mm Hg (p < 0.025), cardiac index increased from 2.5 ± 0.1 to 3.7 ± 0.2
I/min/m2 (p < 0.001) and stroke volume index increased from 30 ± 2 to 39 ± 2 mI/m' (p < 0.001).
The effects of hydralazine on exercise hemodynamics were evaluated in 12 patients. Before treatment, the patients exercised at increasing work loads until limited by symptoms. After hydralazine therapy, exercise was repeated at identical work loads. Although exercise alone resulted in a reduction in systemic vascular resistance, from 1385 ± 88 to 1111 ± 118 dyn-sec-cm-, the addition of hydralazine caused a further reduction in resistance, from 1111 ± 118 to 755 ± 72 dyn-sec-cm' (p < 0.005). Hydralazine reduced pulmonary artery wedge pressure during exercise from 27 ± 2 to 21 ± 1 mm Hg and increased cardiac index from 3.7 ± 0.3 to 4.9 ± 0.3 1/min/m2 (bothp < 0.001) and stroke volume index from 36 ± 3 to 45 ± 2 ml/in (p < 0.005).
All 16 patients were discharged on hydralazine therapy and their clinical course was followed. A marked improvement in symptoms from New York Heart Association functional class III-VI to class I-II, which was sustained for at least 6 months, occurred in seven patients (44%). One patient improved from class IV to class III. The mean follow-up in these eight patients has been 13 ± 4 months. In four of the eight remaining patients, hydralazine was discontinued because of intolerable side effects. Mitral valve surgery was performed in three of these patients as well as in four patients who demonstrated an initial hemodynamic response to therapy but failed to experience symptomatic improvement.
These data demonstrate that hydralazine therapy results in substantial improvement in cardiac performance in patients with mitral regurgitation. The beneficial effects seen at rest are maintained during exercise. The acute improvement in hemodynamics resulted in sustained clinical improvement in half the patients with mitral regurgitation; the other half needed valve surgery. Arterial dilator therapy is of benefit for some patients with severe mitral regurgitation.
IN PATIENTS with mitral regurgitation, the distribution of left ventricular stroke volume is strongly influenced by the level of aortic impedance. When impedance is reduced, forward cardiac output increases and regurgitant flow decreases.'14 Arterial dilators favorably affect resting cardiac performance in mitral regurgitation by causing such a redistribution in flow.5 8 However, most patients complain of symptoms that either occur or worsen only during exercise. Because total systemic vascular resistance is often substantially reduced during exercise, the additional effects of arterial dilators are uncertain and need to be evaluated. The clinical response to long-term therapy is also unknown. Therefore, we studied the effects of arterial dilation with hydralazine"'2 on rest and exercise hemodynamics in a group of patients with isolated, severe mitral regurgitation and evaluated the clinical response to long-term therapy.
The clinical characteristics of the 16 patients with severe mitral regurgitation who were included in the study are listed in table 1. Informed consent was obtained from all patients. The 12 males and four females averaged 57 years of age (range 45-71 years). All were in New York Heart Association (NYHA) functional class III or IV. Mitral regurgitation was attributed to ruptured chordae tendineae in three patients, to rheumatic disease in three, to coronary artery disease in three and to a variety of causes or to an unknown cause in the remainder. Patients with associated mitral stenosis or other valvular lesions were excluded.
Before initiation of the study, all patients underwent complete right-and left-heart catheterization and left ventriculography. The procedure and methods of analysis used at our institution have been described.'38 14 The mean left ventricular end-diastolic volume was 160 ± 17 ml/m2 (± SEM) (table 1). In two patients, quantitation of left ventricular volume and ejection fraction was impossible due to technical factors. The mean ejection fraction was 0.54 ± 0.05; four patients had an ejection fraction less than 0.50. Regurgitant stroke volume averaged 43 + 6 ml/M2 and the regurgitant fraction was 0.55 ± 0.05. All ergometer. Exercise was begun at 200 kpm and continued for 4 minutes. After 4-5 minutes of recovery, the work load was increased in 100-200-kpm increments until the maximal work load defined by exercise-limiting symptoms was reached. Pressures and cardiac output were measured during each stage.
Oral hydralazine was administered at an initial dose of 50-75 mg. The dose was increased by 25 mg every 3-4 hours provided that heart rate did not increase by more than 15 beats/min, mean arterial pressure did not decrease by . 15 mm Hg, diastolic blood pressure was not less than 55-60 mm Hg in patients with coronary artery disease and patients did not develop limiting side effects such as angina, postural hypotension, headache or gastrointestinal disturbance. The optimal dose of hydralazine was considered to be the dose that resulted in the greatest increase in stroke volume without provoking unwanted side effects or symptoms. When necessary to minimize side effects, the dosage of hydralazine was adjusted within the range that produced a positive hemodynamic response. Patients received optimal-dose hydralazine for 24 hours before the final measurements at rest and during exercise were obtained 2-3 hours after a dose of the drug. Exercise was repeated using the same protocol and patients exercised at the same work load as before treatment with hydralazine.
Statistical Analysis
Measurements of pressures and flow before treatment were compared with those obtained after hydralazine by paired t test using two-way tables (1 degree of freedom); p < 0.05 was considered significant. 
Follow-up Evaluation
All 16 patients were discharged hydralazine therapy and their su course was closely followed.
Results
The optimal oral dose of hydrala 50-225 mg every 6-12 hours. The drug measurements of pressures ai obtained at rest are listed in tabi resulted in a small but significant r pulmonary artery wedge pressure, f Hg. The pulmonary artery V wave cantly reduced, from 34 to 23 mm F duction occurred in patients with th initially (table 2, patients 4, 6, 8, 1 Hydralazine increased cardiac in( stroke volume index by 30%. S resistance was significantly reduced, dyn-sec-cm-1. Pulmonary vasculai reduced in all but three patients and decreased from 159 to 113 dyn-sec-c hydralazine on cardiac performance in figure 1 .
The control and posthydralazine pressures and cardiac output dui shown in table 3. The maximal wc patients who underwent exercise sti 200-500 kpm. Exercise was limitei breath or fatigue in all cases an perienced chest pain. During the co cise alone led to a reduction in resistance from a resting level of 13: 1111 dyn-sec-cm-5. However, pulmo pressure increased in all patients, an f-1r the ariin wu,c creased from 17 mm Hg at rest to 27 mm Hg during exercise. Pulmonary artery wedge pressure exceeded 25 mm Hg in seven of 12 patients during control exercise. After hydralazine, when patients were exercised at identical work loads, systemic vascular resistance was reduced from 1111 to 755 dyn-sec-cm-and pulmonary artery wedge pressure was reduced from 27 to 21 mm Hg. Compared with measurements obtained during control exercise, only three patients had elevation in pulmonary artery wedge pressure of 25 mm Hg or greater. Hydralazine also resulted in a 32% increase in cardiac index and a 25% increase in stroke volume. Although stroke volume was 35 ml/m2 or less in six patients during control exercise, only one patient had a value below this level after hydralazine. Pulmonary vascular resistance was reduced by hydralazine in all but two patients, and for the group was decreased from 126 to 88 dyn-sec-cm-. The effects of hydralazine on cardiac performance during exercise are shown in figure 1. C  H  C  H  C  H  C  H  C  H  1  92  90  108  100  12  15  6  7  --2  92  95  120  114  52  48  26  24  --3  80  108  77  65  16  18  10  10  14  12   4  68  84  73  67  34  25  20  16  43  29  5  100  104  87  83  35  45  20  25  30  30  6  90  100  96  92  30  27  20  20  40  30  7  66  90  72  96  18  28  12  12  27 Abbreviations: HR = heart rate; MAP = mean arterial pressure; PAP mean pulmonary artery pressure; PAWPpulmonary artery wedge pressure; V wave = pulmonary artery wedge V wave; CI -cardiac index; SVI = stroke volume index; SVR = systemnic vascular resistance; PVR = pulmonary vascular resistance; q6H = every 6 hours; q8H = every 8 hours; ql2H = every 12 hours; C = control; H = hydralazine. sustained relief of heart failure symptoms; in oneAt rest, hydralazine increased heart rate sigfourth of the patients, side effects necessitated disconnificantly despite only minor reduction in arterial tinuation of therapy; and in the remainder, subpressure. We have noted similar changes in patients stantial clinical improvement did not occur despite with aortic insufficiency treated with hydralazine. 1 evidence of improved hemodynamics during the acute The presumed mechanism is a direct effect of hydraladrug trial.
zine on the automaticity of the sinus node.17 There was a small but significant reduction in pulmonary artery wedge pressure that was due mainly to a reduction in the V-wave amplitude. Although pulmonary artery wedge was reduced by 3 mm Hg or less in eight patients (50%), patients 8, 9 and 15 had substantial reductions. Hydralazine increased cardiac index by 48% and stroke volume by 30%. These changes are similar to those reported with the use of arterial dilators in patients with mitral regurgitation.`Hydralazine has been shown to improve cardiac performance by favorably redistributing total left ventricular stroke volume so that forward cardiac output is increased at the expense of regurgitant flow.8 End-diastolic volume and ejection fraction change little, at least after acute administration of the drug. The initial level of systemic vascular resistance in our patients was only 1385 ± 88 dyn-sec-cm and normal control values (less than 1300 dyn-sec-cm B) were noted in Exercise has been shown to increase the hemodynamic burden on the left ventricle in patients with mitral regurgitation'8 and was important in identifying hemodynamic abnormalities in several of our patients whose resting values were normal. Initially, five of the 12 patients who subsequently performed exercise had normal mean pulmonary artery wedge pressures at rest. Normal left atrial pressures have been reported in patients with severe mitral regurgitation. '9' 20 In such cases, chronic changes in the left atrium help absorb the regurgitant flow so that pressure is not increased. With exercise, pressures increased and exceeded normal limits in all 12 patients. In addition to the increased hemodynamic burden, some of our patients may have developed exerciseinduced abnormalities of left ventricular systolic puinp function. Reduced ejection fraction has been demonstrated during exercise in some patients with aortic insufficiency.2' However, the effects of exercise on left ventricular systolic pump function were not investigated.
Although exercise alone caused a reduction in systemic vascular resistance from 1385 to 1111 dynsec-cm-5, the addition of hydralazine significantly reduced resistance, from 1111 to 755 dyn-sec-cm-.
This resulted in a significant reduction in mean pulmonary artery wedge pressure, from 27 to 21 mm Hg, and an increase of 32% in cardiac index and 27% in stroke volume. These data show that although systemic vascular resistance was modestly reduced by exercise alone, this reduction did not adequately compensate for the increased hemodynamic burden faced by the left ventricle in mitral regurgitation. A further reduction in vascular resistance with hydralazine substantially improved cardiac performance. As discussed above, these data suggest that the autoregulatory response of the systemic vascular bed during exercise is not optimal in patients with mitral regurgitation. Alternatively, the peripheral vasodilatory response to exercise has been shown to be defective in patients with heart failure.22 This might have been a factor in some of our patients. before and after treatment with hydralazine. Although cardiac performance at identical work loads was substantially improved by treatment ( fig. 1) , the effect of therapy on duration of exercise and maximal work load that can be achieved remains uncertain.
Previous reports contain little or no information concerning the long-term clinical effects of arterial dilation in patients with mitral regurgitation.5-8 The finding that approximately 25% of our patients could not tolerate therapy because of side effects is similar to observations made in patients with chronic congestive heart failure who were maintained on vasodilators. 23 Of the nine patients who either had side effects from therapy (four patients) or remained markedly limited by symptoms of heart failure (four with a poor clinical response, one patient who improved to NYHA class III) uncomplicated surgical intervention was undertaken in seven patients within 3 months and usually within 1 month of the initiation of the drug trial. Surgery has been deferred in the two other patients because of poor underlying left ventricular function in one and reluctance to undergo surgery in the other. Therefore, the initiation of surgery need not be unduly prolonged (and the risk of left ventricular decompensation increased) by a clinical trial with hydralazine. In the remaining seven patients who had initial symptomatic relief to NYHA functional class I-II, the improvement has been sustained for 13 ± 4 months. The two patients who experienced worsening symptoms after an initial improvement had evidence of depressed ejection fraction at the initial catheterization, and their subsequent course probably reflects further deterioration of left ventricular systolic pump function.
The long-term effects of arterial dilation on left ventricular volumes and systolic pump function have not been addressed in this study. Previous studies have shown that in patients with aortic insufficiency, reduction in chamber size and improvement in ejection fraction may occur after successful valve replacement. '3, 24, 25 We have shown that such improvement is also possible in patients with aortic insufficiency when regurgitant flow is reduced by long-term treatment with hydralazine.28 At present, the few patients with mitral regurgitation who are being maintained on hydralazine have not had a significant change in ventricular size or in pump function as assessed by M-mode echocardiography.
Clinical Implications
The measurement of exercise hemodynamics is of value in the assessment of patients with mitral regurgitation when resting hemodynamics are normal or borderline. Few patients lead a life with no effort; therefore, the evaluation of therapeutic interventions should include studies performed both at rest and during exercise. Arterial dilation with hydralazine improves cardiac performance at rest and during exercise in patients with mitral regurgitation and appears to be a reasonably effective form of long-term therapy in some patients. The long-term effects of arterial dilator therapy on left ventricular volumes and systolic pump Our patients exercised at identical work loads
